Tango Therapeutics (TNGX)
NASDAQ:TNGX
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:55Neutral
Price Target:
$20.50
▲(3.22% Upside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by weak financial performance driven by large operating losses and substantial cash burn, despite a relatively solid balance sheet. Technicals are a meaningful positive with strong trend and momentum, though the overbought RSI adds near-term risk. Valuation is constrained by unprofitability, while corporate events are supportive but secondary.
Positive Factors
Balance Sheet Strength
A low debt-to-equity ratio and materially higher equity versus 2024 provide financial flexibility to fund clinical programs and absorb development delays. This reduces near-term refinancing risk and supports execution of registrational studies over the next several quarters.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow at this scale requires near-term financing, partnerships, or milestone receipts to fund registrational trials. Persistent burn elevates dilution and execution risk if non-dilutive funding does not arrive as expected.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A low debt-to-equity ratio and materially higher equity versus 2024 provide financial flexibility to fund clinical programs and absorb development delays. This reduces near-term refinancing risk and supports execution of registrational studies over the next several quarters.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.83B
Dividend YieldN/A
Average Volume (3M)3.04M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth53.28%
EPS Growth21.77%
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding142,688,860
10 Day Avg. Volume3,795,201
30 Day Avg. Volume3,037,748
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue35.72
Enterprise Value/Gross Profit36.70
Enterprise Value/Ebitda-21.21
Forecast
1Y Price Target
$20.67Price Target Upside4.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$7.41M
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as...
How the Company Makes Money
Tango Therapeutics generates revenue primarily through collaboration and licensing arrangements rather than product sales (as it is a clinical-stage company). Under such agreements, the company can earn (i) upfront payments for granting partners r...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -109.01M | -143.10M | -111.76M | -109.46M | -57.29M |
| Net Income | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | |||||
| Total Assets | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | |||||
| Free Cash Flow | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Positive
19.86
Price Trends
14.13
Positive
11.63
Positive
9.22
Positive
Market Momentum
1.90
Negative
71.47
Negative
75.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 19.86 is above the 20-day moving average (MA) of 16.89, above the 50-day MA of 14.13, and above the 200-day MA of 9.22, indicating a bullish trend. The MACD of 1.90 indicates Negative momentum. The RSI at 71.47 is Negative, neither overbought nor oversold. The STOCH value of 75.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $2.83B | -10.13 | -50.30% | ― | 53.28% | 21.77% | |
55 Neutral | $2.25B | -13.11 | -25.30% | ― | ― | 63.85% | |
53 Neutral | $849.98M | -6.70 | -100.29% | ― | 5459.66% | -59.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.31B | -5.79 | -39.69% | ― | -27.61% | -69.49% | |
50 Neutral | $657.21M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
50 Neutral | $529.04M | -10.19 | -28.71% | ― | ― | ― |
* Healthcare Sector Average
TNGX
Tango Therapeutics
19.86
18.25
1133.54%
ORKA
Oruka Therapeutics
45.46
33.51
280.42%
IMTX
Immatics
9.77
5.06
107.43%
SPRY
ARS Pharmaceuticals
8.56
-4.07
-32.22%
PRME
Prime Medicine, Inc.
3.64
1.64
82.00%
UPB
Upstream Bio, Inc.
9.79
2.98
43.76%
Tango Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics appoints new CEO amid leadership transition
Positive
Jan 8, 2026
On January 8, 2026, Tango Therapeutics announced a planned leadership transition in which founding chief executive Barbara Weber, M.D., retired from the CEO role and became Executive Chair for 2026, moving to non-executive chair in 2027, while rem...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Adds Independent Director to Strengthen Governance
Positive
Jan 5, 2026
On January 2, 2026, Tango Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed Sung H. Lee as an independent Class I director, with a term running until the 2028 annual meeting of stockholders. Lee, a season...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.